Biosyent Stock Current Liabilities
RX Stock | CAD 11.35 0.09 0.80% |
Biosyent fundamentals help investors to digest information that contributes to Biosyent's financial success or failures. It also enables traders to predict the movement of Biosyent Stock. The fundamental analysis module provides a way to measure Biosyent's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biosyent stock.
At this time, Biosyent's Total Current Liabilities is fairly stable compared to the past year. Non Current Liabilities Other is likely to climb to about 1.7 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 851.1 K in 2024. Biosyent | Current Liabilities |
Biosyent Company Current Liabilities Analysis
Biosyent's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Biosyent Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Biosyent is extremely important. It helps to project a fair market value of Biosyent Stock properly, considering its historical fundamentals such as Current Liabilities. Since Biosyent's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biosyent's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biosyent's interrelated accounts and indicators.
Click cells to compare fundamentals
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
Competition |
Biosyent Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Biosyent has a Current Liabilities of 0.0. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The current liabilities for all Canada stocks is 100.0% higher than that of the company.
Biosyent Current Valuation Drivers
We derive many important indicators used in calculating different scores of Biosyent from analyzing Biosyent's financial statements. These drivers represent accounts that assess Biosyent's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Biosyent's important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 85.1M | 102.8M | 104.8M | 107.0M | 96.3M | 101.1M | |
Enterprise Value | 73.5M | 84.2M | 88.3M | 100.2M | 90.2M | 94.7M |
Biosyent Fundamentals
Return On Equity | 0.21 | ||||
Return On Asset | 0.13 | ||||
Profit Margin | 0.21 % | ||||
Operating Margin | 0.22 % | ||||
Current Valuation | 115.61 M | ||||
Shares Outstanding | 11.59 M | ||||
Shares Owned By Insiders | 33.63 % | ||||
Shares Owned By Institutions | 1.41 % | ||||
Number Of Shares Shorted | 357 | ||||
Price To Earning | 16.61 X | ||||
Price To Book | 3.52 X | ||||
Price To Sales | 3.89 X | ||||
Revenue | 31.59 M | ||||
Gross Profit | 22.86 M | ||||
EBITDA | 7.99 M | ||||
Net Income | 6.46 M | ||||
Cash And Equivalents | 22.46 M | ||||
Cash Per Share | 1.59 X | ||||
Total Debt | 1.22 M | ||||
Current Ratio | 10.10 X | ||||
Book Value Per Share | 2.96 X | ||||
Cash Flow From Operations | 5.83 M | ||||
Short Ratio | 0.01 X | ||||
Earnings Per Share | 0.60 X | ||||
Target Price | 11.75 | ||||
Beta | 0.93 | ||||
Market Capitalization | 131.59 M | ||||
Total Asset | 41.53 M | ||||
Retained Earnings | 27.53 M | ||||
Working Capital | 30.34 M | ||||
Annual Yield | 0.02 % | ||||
Net Asset | 41.53 M |
About Biosyent Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biosyent's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biosyent using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biosyent based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Biosyent Stock Analysis
When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.